Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers

This study is a randomized, double‐blind, placebo‐controlled, single‐dose andmultiple‐dose, dose‐escalation phase I clinical trial, aiming to evaluate the safety,tolerability, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity ofMWN105 injection in healthy Chinese volunteers, and to provide a reference for the nextclinical trial.This study includes a single ascending dose (SAD) study and a multiple ascending dose(MAD) study. The SAD study consists of 4 dose groups; the MAD study consists of 2 dosegroups and adopts a 4‐week dose titration scheme.The study plans to enroll 55 volunteers. The primary endpoint is the incidence of adverseevents. The secondary endpoints are the pharmacokinetic and pharmacodynamiccharacteristics and immunogenicity endpoints.